Amid intensifying scrutiny over the cost of insulin, a new analysis finds that total Medicare Part D spending on this diabetes treatment rose 840 percent in the decade between 2007 and 2017, from $1.4 billion to $13.3 billion, thanks to both rising prices and a growing number of patients.

Average spending per person increased by 358 percent between 2007 and 2016, from $862 to $3,949. Aggregate out-of-pocket spending quadrupled from $236 million to $968 million. And among enrollees without low-income subsidies, average per capita out-of-pocket spending on insulin nearly doubled during that period, from $324 to $588, according to the Kaiser Family Foundation analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Health insurance company Cigna is trying to control skyrocketing insulin cost for a few of its diabetic patients. It is planning to launch a new program next year, which will shells out $25 for their monthly supply of insulin.

  • Are there any good statistics that came out of Obama’s tenure? Record healthcare costs, record suicides, record STDs could go on for a while.

  • Why highlight this garbage study? The data analysis excludes rebates in a *very* highly-rebated category. The “research” sheds light only on the biases of the researchers and their sponsor (Guess who?), not on “larger trends.”

    The authors offer two small paragraphs about rebates, but their figures are very, very wrong. The “average” rebate figures vastly underestimate actual rebate rates for insulin. Those rebates have grown dramatically over the period of study, which is why net (post-rebate) insulin prices have been flat/down. A small disclaimer doesn’t overcome the numerous breathless color charts.

    For shame, Ed.

    • Hi Adam
      Thanks for the note and I understand your points.
      Yes, the study does have the disclaimer about rebates, and the story does note the net price effect, at least for Lilly, since the company recently disclosed some data.
      If nothing else, the study underscores the ongoing need for the actual data so we can understand the real costs.
      Regards
      ed at pharmalot

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy